REFERENCES
1. Jinjie Y, Sun N, Zhang S, Feng X, Chen X, Zhao D, et al. A rapid
HPLC-MS/MS method for determining busulfan in hemolysis samples from
children with hematopoietic stem cell transplantation. Biomedical
chromatography : BMC. 2020:e4898.
2. ten Brink MH, Zwaveling J, Swen JJ, Bredius RG, Lankester AC,
Guchelaar HJ. Personalized busulfan and treosulfan conditioning for
pediatric stem cell transplantation: the role of pharmacogenetics and
pharmacokinetics. Drug Discov Today. 2014;19(10):1572-86.
3. Dix SP, Wingard JR, Mullins RE, Jerkunica I, Davidson TG, Gilmore CE,
et al. Association of busulfan area under the curve with veno-occlusive
disease following BMT. Bone Marrow Transplant. 1996;17(2):225-30.
4. Geddes M, Kangarloo SB, Naveed F, Quinlan D, Chaudhry MA, Stewart D,
et al. High busulfan exposure is associated with worse outcomes in a
daily i.v. busulfan and fludarabine allogeneic transplant regimen.
Biology of blood and marrow transplantation : journal of the American
Society for Blood and Marrow Transplantation. 2008;14(2):220-8.
5. Bartelink IH LA, Elisabeth ML, et al . Association of busulfan
exposure with survival and toxicity after haemopoietic cell
transplantation in children and young adults: a multicentre,
retrospective cohort analysis. Lancet Haematol .
2016;3(11):e526–e36.
6. Ayala E, Figueroa J, Perkins J, Kim J, Yue B, Riches M, et al.
Myeloablative intravenous pharmacokinetically targeted busulfan plus
fludarabine as conditioning for allogeneic hematopoietic cell
transplantation in patients with non-Hodgkin lymphoma. Clinical
lymphoma, myeloma & leukemia. 2015;15(6):335-40.
7. Parmar S, Rondon G, de Lima M, Thall P, Bassett R, Anderlini P, et
al. Dose intensification of busulfan in the preparative regimen is
associated with improved survival: a phase I/II controlled, randomized
study. Biology of blood and marrow transplantation : journal of the
American Society for Blood and Marrow Transplantation.
2013;19(3):474-80.
8. Andersson BS, Valdez BC, de Lima M, Wang X, Thall PF, Worth LL, et
al. Clofarabine ± fludarabine with once daily i.v. busulfan as
pretransplant conditioning therapy for advanced myeloid leukemia and
MDS. Biology of blood and marrow transplantation : journal of the
American Society for Blood and Marrow Transplantation.
2011;17(6):893-900.
9. Malar R, Sjoo F, Rentsch K, Hassan M, Gungor T. Therapeutic drug
monitoring is essential for intravenous busulfan therapy in pediatric
hematopoietic stem cell recipients. Pediatr Transplant.
2011;15(6):580-8.
10. Wall DA, Chan KW, Nieder ML, Hayashi RJ, Yeager AM, Kadota R, et al.
Safety, efficacy, and pharmacokinetics of intravenous busulfan in
children undergoing allogeneic hematopoietic stem cell transplantation.
Pediatr Blood Cancer. 2010;54(2):291-8.
11. Czerwinski M, Gibbs JP, Slattery JT. Busulfan conjugation by
glutathione S-transferases alpha, mu, and pi. Drug metabolism and
disposition: the biological fate of chemicals. 1996;24(9):1015-9.
12. Gibbs JP, Czerwinski M, Slattery JT. Busulfan-glutathione
conjugation catalyzed by human liver cytosolic glutathione
S-transferases. Cancer research. 1996;56(16):3678-81.
13. Huezo-Diaz P, Uppugunduri CR, Tyagi AK, Krajinovic M, Ansari M.
Pharmacogenetic aspects of drug metabolizing enzymes in busulfan based
conditioning prior to allogenic hematopoietic stem cell transplantation
in children. Current drug metabolism. 2014;15(3):251-64.
14. Choi B, Kim MG, Han N, Kim T, Ji E, Park S, et al. Population
pharmacokinetics and pharmacodynamics of busulfan with GSTA1
polymorphisms in patients undergoing allogeneic hematopoietic stem cell
transplantation. Pharmacogenomics. 2015;16(14):1585-94.
15. Abbasi N, Vadnais B, Knutson JA, Blough DK, Kelly EJ, O’Donnell PV,
et al. Pharmacogenetics of intravenous and oral busulfan in
hematopoietic cell transplant recipients. Journal of clinical
pharmacology. 2011;51(10):1429-38.
16. Yin J, Xiao Y, Zheng H, Zhang YC. Once-daily i.v. BU-based
conditioning regimen before allogeneic hematopoietic SCT: a study of
influence of GST gene polymorphisms on BU pharmacokinetics and clinical
outcomes in Chinese patients. Bone Marrow Transplant.
2015;50(5):696-705.
17. Hassan M, Ljungman P, Bolme P, Ringden O, Syruckova Z, Bekassy A, et
al. Busulfan bioavailability. Blood. 1994;84(7):2144-50.
18. Gibbs JP, Murray G, Risler L, Chien JY, Dev R, Slattery JT.
Age-dependent tetrahydrothiophenium ion formation in young children and
adults receiving high-dose busulfan. Cancer research.
1997;57(24):5509-16.
19. Gibbs JP, Liacouras CA, Baldassano RN, Slattery JT. Up-regulation of
glutathione S-transferase activity in enterocytes of young children.
Drug metabolism and disposition: the biological fate of chemicals.
1999;27(12):1466-9.
20. Ansari M, Rezgui MA, Theoret Y, Uppugunduri CR, Mezziani S, Vachon
MF, et al. Glutathione S-transferase gene variations influence BU
pharmacokinetics and outcome of hematopoietic SCT in pediatric patients.
Bone Marrow Transplant. 2013;48(7):939-46.
21. Zwaveling J, Press RR, Bredius RG, van Derstraaten TR, den Hartigh
J, Bartelink IH, et al. Glutathione S-transferase polymorphisms are not
associated with population pharmacokinetic parameters of busulfan in
pediatric patients. Ther Drug Monit. 2008;30(4):504-10.
22. Kusama M, Kubota T, Matsukura Y, Matsuno K, Ogawa S, Kanda Y, et al.
Influence of glutathione S-transferase A1 polymorphism on the
pharmacokinetics of busulfan. Clin Chim Acta. 2006;368(1-2):93-8.
23. Rocha V, Porcher R, Fernandes JF, Filion A, Bittencourt H, Silva W,
Jr., et al. Association of drug metabolism gene polymorphisms with
toxicities, graft-versus-host disease and survival after HLA-identical
sibling hematopoietic stem cell transplantation for patients with
leukemia. Leukemia. 2009;23(3):545-56.
24. Vassal G, Deroussent A, Challine D, Hartmann O, Koscielny S,
Valteau-Couanet D, et al. Is 600 mg/m2 the appropriate dosage of
busulfan in children undergoing bone marrow transplantation? Blood.
1992;79(9):2475-9.
25. Bertholle-Bonnet V, Bleyzac N, Galambrun C, Mialou V, Bertrand Y,
Souillet G, et al. Influence of underlying disease on busulfan
disposition in pediatric bone marrow transplant recipients: a
nonparametric population pharmacokinetic study. Ther Drug Monit.
2007;29(2):177-84.
26. Nguyen L, Fuller D, Lennon S, Leger F, Puozzo C. I.V. busulfan in
pediatrics: a novel dosing to improve safety/efficacy for hematopoietic
progenitor cell transplantation recipients. Bone Marrow Transplant.
2004;33(10):979-87.
27. Aouri M, Barcelo C, Guidi M, Rotger M, Cavassini M, Hizrel C, et al.
Population Pharmacokinetics and Pharmacogenetics Analysis of Rilpivirine
in HIV-1-Infected Individuals. Antimicrobial agents and chemotherapy.
2017;61(1).
28. Ette EI, Ludden TM. Population pharmacokinetic modeling: the
importance of informative graphics. Pharmaceutical research.
1995;12(12):1845-55.
29. Karlsson MO, Savic RM. Diagnosing Model Diagnostics. Clinical
Pharmacology & Therapeutics. 2007;82(1):17-20.
30. Hooker AC, Staatz CE, Karlsson MO. Conditional weighted residuals
(CWRES): a model diagnostic for the FOCE method. Pharmaceutical
research. 2007;24(12):2187-97.
31. Ette EI. Stability and performance of a population pharmacokinetic
model. Journal of clinical pharmacology. 1997;37(6):486-95.
32. van der Galiën R, Boveneind-Vrubleuskaya NV, Peloquin C, Skrahina A,
Touw DJ, Alffenaar JC. Pharmacokinetic Modeling, Simulation, and
Development of a Limited Sampling Strategy of Cycloserine in Patients
with Multidrug-/Extensively Drug-Resistant Tuberculosis. Clin
Pharmacokinet. 2020;59(7):899-910.
33. Nankivell BJ, Gruenewald SM, Allen RD, Chapman JR. Predicting
glomerular filtration rate after kidney transplantation.
Transplantation. 1995;59(12):1683-9.
34. Jones RJ, Lee KS, Beschorner WE, Vogel VG, Grochow LB, Braine HG, et
al. Venoocclusive disease of the liver following bone marrow
transplantation. Transplantation. 1987;44(6):778-83.
35. Harris AC, Young R, Devine S, Hogan WJ, Ayuk F, Bunworasate U, et
al. International, Multicenter Standardization of Acute
Graft-versus-Host Disease Clinical Data Collection: A Report from the
Mount Sinai Acute GVHD International Consortium. Biology of blood and
marrow transplantation : journal of the American Society for Blood and
Marrow Transplantation. 2016;22(1):4-10.
36. Kim MG, Kwak A, Choi B, Ji E, Oh JM, Kim K. Effect of glutathione
S-transferase genetic polymorphisms on busulfan pharmacokinetics and
veno-occlusive disease in hematopoietic stem cell transplantation: A
meta-analysis. Basic Clin Pharmacol Toxicol. 2019;124(6):691-703.
37. Ansari M, Curtis PH, Uppugunduri CRS, Rezgui MA, Nava T, Mlakar V,
et al. GSTA1 diplotypes affect busulfan clearance and toxicity in
children undergoing allogeneic hematopoietic stem cell transplantation:
a multicenter study. Oncotarget. 2017;8(53):90852-67.
38. Nava T, Kassir N, Rezgui MA, Uppugunduri CRS, Huezo-Diaz Curtis P,
Duval M, et al. Incorporation of GSTA1 genetic variations into a
population pharmacokinetic model for IV busulfan in paediatric
hematopoietic stem cell transplantation. Br J Clin Pharmacol.
2018;84(7):1494-504.
39. Nishikawa T, Yamaguchi H, Ikawa K, Nakayama K, Higashi E, Miyahara
E, et al. Influence of GST polymorphisms on busulfan pharmacokinetics in
Japanese children. Pediatrics international : official journal of the
Japan Pediatric Society. 2019;61(6):558-65.
40. Yee SW, Mefford JA, Singh N, Percival ME, Stecula A, Yang K, et al.
Impact of polymorphisms in drug pathway genes on disease-free survival
in adults with acute myeloid leukemia. Journal of human genetics.
2013;58(6):353-61.
41. Perkins JB, Kim J, Anasetti C, Fernandez HF, Perez LE, Ayala E, et
al. Maximally tolerated busulfan systemic exposure in combination with
fludarabine as conditioning before allogeneic hematopoietic cell
transplantation. Biology of blood and marrow transplantation : journal
of the American Society for Blood and Marrow Transplantation.
2012;18(7):1099-107.
42. Yeh RF, Pawlikowski MA, Blough DK, McDonald GB, O’Donnell PV,
Rezvani A, et al. Accurate targeting of daily intravenous busulfan with
8-hour blood sampling in hospitalized adult hematopoietic cell
transplant recipients. Biology of blood and marrow transplantation :
journal of the American Society for Blood and Marrow Transplantation.
2012;18(2):265-72.
43. de Lima M, Couriel D, Thall PF, Wang X, Madden T, Jones R, et al.
Once-daily intravenous busulfan and fludarabine: clinical and
pharmacokinetic results of a myeloablative, reduced-toxicity
conditioning regimen for allogeneic stem cell transplantation in AML and
MDS. Blood. 2004;104(3):857-64.
44. Russell JA, Tran HT, Quinlan D, Chaudhry A, Duggan P, Brown C, et
al. Once-daily intravenous busulfan given with fludarabine as
conditioning for allogeneic stem cell transplantation: study of
pharmacokinetics and early clinical outcomes. Biology of blood and
marrow transplantation : journal of the American Society for Blood and
Marrow Transplantation. 2002;8(9):468-76.
45. Gürlek Gökçebay D, Azik F, Ozbek N, Isik P, Avci Z, Tavil B, et al.
Clinical comparison of weight- and age-based strategy of dose
administration in children receiving intravenous busulfan for
hematopoietic stem cell transplantation. Pediatr Transplant.
2015;19(3):307-15.
46. McCune JS, Bemer MJ, Barrett JS, Scott Baker K, Gamis AS, Holford
NH. Busulfan in infant to adult hematopoietic cell transplant
recipients: a population pharmacokinetic model for initial and Bayesian
dose personalization. Clinical cancer research : an official journal of
the American Association for Cancer Research. 2014;20(3):754-63.
47. Vaughan WP, Carey D, Perry S, Westfall AO, Salzman DE. A limited
sampling strategy for pharmacokinetic directed therapy with intravenous
busulfan. Biology of blood and marrow transplantation : journal of the
American Society for Blood and Marrow Transplantation.
2002;8(11):619-24.
48. Teitelbaum Z, Nassar L, Scherb I, Fink D, Ring G, Lurie Y, et al.
Limited Sampling Strategies Supporting Individualized Dose Adjustment of
Intravenous Busulfan in Children and Young Adults. Ther Drug Monit.
2020;42(3):427-34.
49. Andersson BS, Thall PF, Madden T, Couriel D, Wang X, Tran HT, et al.
Busulfan systemic exposure relative to regimen-related toxicity and
acute graft-versus-host disease: defining a therapeutic window for i.v.
BuCy2 in chronic myelogenous leukemia. Biology of blood and marrow
transplantation : journal of the American Society for Blood and Marrow
Transplantation. 2002;8(9):477-85.
50. Lee JW, Kang HJ, Lee SH, Yu KS, Kim NH, Yuk YJ, et al. Highly
variable pharmacokinetics of once-daily intravenous busulfan when
combined with fludarabine in pediatric patients: phase I clinical study
for determination of optimal once-daily busulfan dose using
pharmacokinetic modeling. Biology of blood and marrow transplantation :
journal of the American Society for Blood and Marrow Transplantation.
2012;18(6):944-50.
51. McPherson ME, Hutcherson D, Olson E, Haight AE, Horan J, Chiang KY.
Safety and efficacy of targeted busulfan therapy in children undergoing
myeloablative matched sibling donor BMT for sickle cell disease. Bone
Marrow Transplant. 2011;46(1):27-33.
52. Davis JM, Ivanova A, Chung Y, Shaw JR, Rao KV, Ptachcinski JR, et
al. Evaluation of a Test Dose Strategy for Pharmacokinetically-Guided
Busulfan Dosing for Hematopoietic Stem Cell Transplantation. Biology of
blood and marrow transplantation : journal of the American Society for
Blood and Marrow Transplantation. 2019;25(2):391-7.
53. Srivastava A, Poonkuzhali B, Shaji RV, George B, Mathews V, Chandy
M, et al. Glutathione S-transferase M1 polymorphism: a risk factor for
hepatic venoocclusive disease in bone marrow transplantation. Blood.
2004;104(5):1574-7.
54. Krivoy N, Hoffer E, Lurie Y, Bentur Y, Rowe JM. Busulfan use in
hematopoietic stem cell transplantation: pharmacology, dose adjustment,
safety and efficacy in adults and children. Current drug safety.
2008;3(1):60-6.
55. Demirer T, Buckner CD, Appelbaum FR, Bensinger WI, Sanders J,
Lambert K, et al. Busulfan, cyclophosphamide and fractionated total body
irradiation for autologous or syngeneic marrow transplantation for acute
and chronic myelogenous leukemia: phase I dose escalation of busulfan
based on targeted plasma levels. Bone Marrow Transplant.
1996;17(4):491-5.